Clinical trial
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00077194 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00077194 |
|---|---|
| Title | FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study Of Depsipeptide, A Histone Deacetylase Inhibitor, In Relapsed Or Refractory Mantle Cell Or Diffuse Large Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | romidepsin |
| Enrollment | 35 |
| Start date | Jan 1, 2004 |
| Primary completion | Dec 1, 2005 |
| First posted | Feb 11, 2004 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: